Dossier
obesity business
Coverage of obesity business in the Nexus archive.
- Novo Nordisk's raised forecast fails to change the debate over its obesity business
Novo Nordisk raised its forecast for its obesity business, but Wall Street remains unconvinced about its ability to achieve sustainable growth amid intensifying competition from Eli Lilly.